Will Grove Collaborative Make it Over the Goal Line?

by | Jun 2, 2022

The Branson-backed sustainable consumer goods company reports soft Q1 results ahead of 6.14 merger vote

————————————————-
Free Investor Resources from Boardroom Alpha
—————————————————-
** Podcast: Know Who Drives Return
** Daily SPAC Newsletter
** Full SPAC Listing

Grove Collaborative Announces Q1 Earnings Results

Grove Collaborative announced disappointing Q1 earnings results, with revenues and margins showing sequential and YoY declines. The sustainable consumer goods company has a DA with Richard Branson-backed Virgin Group Acquisition Corp. II (VGII). Grove’s Q1 revenue of $90.5 million declined 11% year-over-year. EBITDA margin deteriorated considerably — (43.8)% versus (30.7)% in the first quarter of 2021Q4 2021.

The company issued revised 2022, 2033 and 2024 guidance. Notably, 2022 revenue guidance calls for a YoY revenue decline of 21% at the midpoint (Grove’s 2021 revenues were $383.7 million).

  • 2022E – Net revenue of $300 to $310 million; adjusted EBITDA margin of -29% to -32%
  • 2023E – Net revenue of $300 to $310 million; adjusted EBITDA margin of -13% to -16%
  • 2024E – Net revenue of $330 to $360 million; adjusted EBITDA margin of greater than 0%

Despite bold plans to launch multiple sustainable brands spanning the personal care, paper and beauty categories, Grove laid off approximately 17% of its workforce in March. The transaction, which is expected to close in Q2, values Grove at $1.5 billion. Merger vote is coming up on 6.14. VGI already announced a $50M backstop back in April.

BSGA Extends Deadline

Blue Safari Group Acquisition Corp. (BSGA) uses first of 2 extensions, adding $0.10 and extending until September 14, 2022. The SPAC has a DA with crypto mining datacenter provider Bitdeer.

Boardroom Alpha SPAC Market Review for May

Time is running out as SPACs scramble to finance deals at almost any cost. Expect more deSPAC duds as sponsors push low-quality companies at onerous valuations — for the simple purpose of protecting at-risk capital. Full report here.

SPAC Calendar

Source: Boardroom Alpha

More from Boardroom Alpha

For ongoing tracking, analytics, and data on SPACs checkout Boardroom Alpha’s SPAC Data and Analytics service.

Recent Analysis

CEO & CFO Moves Review – November 8, 2024

Explore last week’s CEO and CFO transitions at major public companies like Adial Pharmaceuticals, Affirm Holdings, Agrify Corp, and Dollar Tree. Learn about the new leaders taking charge amidst financial challenges, governance risks, and stock performance issues. This update covers executive shifts at companies facing shareholder pressures, regulatory scrutiny, and strategic reorganizations.

Daily SPAC Update – November 7, 2024

ACAB + Abpro SPAC Deal Vote. MCAA Extension Vote. FRLA and INTE Shareholders Extend. ROCL Deal and GLAC Extension Votes Set. ACAB Non-Redemption Agreement.

Subscribe to Boardroom Alpha Newsletters

Subscribe to Boardroom Alpha's research to receive the latest on governance, SPACs, and people.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.